Immunoregulation of Gastrointestinal Carcinogenesis (R01)
National Institutes of Health · Opportunity PA-07-256
Multiple Receipt Dates - See Link to Full Announcement for details.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
About this opportunity
-Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications from researchers interested in the investigations of two aspects of gastrointestinal carcinogenesis, which include: (1) the roles of the mucosal immune system in initiating and maintaining inflammatory responses that contribute to the development of premalignant and malignant gastrointestinal cancers; and/or (2) the molecular mechanism(s) by which immunoregulatory cells dampen inflammation and decrease tumorigenesis. Applications submitted in response to this FOA should be focused on research that will increase our understanding of how the unique gastrointestinal microenvironment shapes mucosal immune responses in the setting of inflammatory disease-associated carcinogenesis. The ultimate goal of this scientific initiative is to generate a comprehensive understanding of how the innate and adaptive immune responses participate in gastrointestinal carcinogenesis. -Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-06-290, that solicits applications under the Exploratory/Developmental Grant (R21) award mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | National Institutes of Health | August 18, 2026 23d left | — | Nonprofits |
| Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | $499k | Nonprofits |
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed) | National Institutes of Health | September 7, 2026 43d left | — | Nonprofits |